ES2276078T3 - Proteina de fusion glicoproteina vi-fc para el tratamiento de enfermedades vasculares. - Google Patents

Proteina de fusion glicoproteina vi-fc para el tratamiento de enfermedades vasculares. Download PDF

Info

Publication number
ES2276078T3
ES2276078T3 ES03735562T ES03735562T ES2276078T3 ES 2276078 T3 ES2276078 T3 ES 2276078T3 ES 03735562 T ES03735562 T ES 03735562T ES 03735562 T ES03735562 T ES 03735562T ES 2276078 T3 ES2276078 T3 ES 2276078T3
Authority
ES
Spain
Prior art keywords
gpvi
collagen
fusion protein
platelet
platelets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03735562T
Other languages
English (en)
Spanish (es)
Inventor
Steffen Massberg
Meinrad Gawaz
Andreas Bultmann
Gotz Munch
Martin Ungerer
Mario Peluso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trigen GmbH
Original Assignee
Trigen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trigen GmbH filed Critical Trigen GmbH
Application granted granted Critical
Publication of ES2276078T3 publication Critical patent/ES2276078T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
ES03735562T 2002-06-07 2003-06-05 Proteina de fusion glicoproteina vi-fc para el tratamiento de enfermedades vasculares. Expired - Lifetime ES2276078T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02012742A EP1369128A1 (en) 2002-06-07 2002-06-07 Inhibitors of glycoprotein VI and their therapeutic use
EP02012742 2002-06-07

Publications (1)

Publication Number Publication Date
ES2276078T3 true ES2276078T3 (es) 2007-06-16

Family

ID=29433140

Family Applications (2)

Application Number Title Priority Date Filing Date
ES03735562T Expired - Lifetime ES2276078T3 (es) 2002-06-07 2003-06-05 Proteina de fusion glicoproteina vi-fc para el tratamiento de enfermedades vasculares.
ES06023943.1T Expired - Lifetime ES2527717T3 (es) 2002-06-07 2003-06-05 Método para producir una proteína de fusión de glucoproteína vi-Fc

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06023943.1T Expired - Lifetime ES2527717T3 (es) 2002-06-07 2003-06-05 Método para producir una proteína de fusión de glucoproteína vi-Fc

Country Status (13)

Country Link
US (1) US7514543B2 (https=)
EP (4) EP1369128A1 (https=)
JP (1) JP4722480B2 (https=)
CN (1) CN1668721B (https=)
AT (1) ATE346095T1 (https=)
AU (2) AU2003250825A1 (https=)
CA (1) CA2488630C (https=)
DE (1) DE60309865T2 (https=)
DK (1) DK1860118T3 (https=)
ES (2) ES2276078T3 (https=)
SI (1) SI1511770T1 (https=)
WO (2) WO2003104282A2 (https=)
ZA (1) ZA200409776B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
GB0511590D0 (en) * 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
WO2006061650A2 (en) * 2004-12-10 2006-06-15 Trigen Gmbh Methods, products and uses involving platelets and/or the vasculature
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
KR101194446B1 (ko) 2004-04-29 2012-10-24 오쓰까 세이야꾸 가부시키가이샤 당단백 ｖｉ에 특이적인 항체 및 그의 제조방법
ATE548389T1 (de) 2004-08-03 2012-03-15 Innate Pharma Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
FR2884831B1 (fr) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
EP1876240B1 (en) * 2005-04-28 2012-08-22 Mochida Pharmaceutical Co., Ltd. Anti-human platelet membrane glycoprotein vi monoclonal antibody
JP5224707B2 (ja) * 2005-04-28 2013-07-03 持田製薬株式会社 抗血小板膜糖蛋白質ｖｉモノクローナル抗体
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
CN101341406A (zh) * 2005-12-22 2009-01-07 盐野义制药株式会社 急性冠状综合征的预后预测方法
SG185307A1 (en) * 2007-10-31 2012-11-29 Otsuka Pharma Co Ltd Uses of a glycoprotein vi (gpvi) inhibitor
ES2569610T3 (es) * 2008-12-04 2016-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Método para producir plaquetas
PL2995315T3 (pl) * 2009-05-15 2024-04-22 University Health Network Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47
EP2397495A1 (en) * 2010-06-21 2011-12-21 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2336188A1 (en) * 2009-12-18 2011-06-22 Sanofi-Aventis Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
PT2513147T (pt) 2009-12-18 2016-10-11 Sanofi Sa Novos anticorpos antagonistas e seus fragmentos fab contra gpvi e utilizações destes
EP2377888A1 (en) 2010-04-07 2011-10-19 Corimmun GmbH Fusion protein
ES2914814T3 (es) 2012-12-17 2022-06-16 Pf Argentum Ip Holdings Llc Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
US20150338330A1 (en) * 2012-12-20 2015-11-26 Fujimori Kogyo Co., Ltd., Method for Comprehensive Assessment of Platelet Aggregation
EP3424957A1 (en) 2017-07-03 2019-01-09 advanceCOR GmbH Fusion protein
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
CN115768784A (zh) * 2020-02-06 2023-03-07 勃林格殷格翰动物保健有限公司 用于检测抗弹状病毒抗体的多肽

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) * 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
ZA887365B (en) 1987-10-02 1990-05-30 Genentech Inc Adheson variants
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
GB9806806D0 (en) 1998-03-30 1998-05-27 Univ Cambridge Tech Peptides and uses thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9810999D0 (en) * 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
DE60038675T2 (de) 1999-05-07 2009-07-02 Sanofi-Aventis Deutschland Gmbh Rekombinantes plättchenkollagenrezeptorglykoprotein und dessen pharmazeutische verwendung
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
AU7097400A (en) 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
US7300922B2 (en) 2001-05-25 2007-11-27 Duke University Modulators of pharmacological agents
WO2003008454A2 (en) 2001-07-18 2003-01-30 Merck Patent Gmbh Glycoprotein vi fusion proteins
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
GB0130832D0 (en) 2001-12-22 2002-02-06 Univ Reading Modulation of the activity of the platelet endothelial cell adhesion molecule-1 (pecam-1)
GB0211750D0 (en) 2002-05-22 2002-07-03 Ouwehand Willem Abnormal blood conditions
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4

Also Published As

Publication number Publication date
CA2488630C (en) 2011-07-05
JP2006512894A (ja) 2006-04-20
DK1860118T3 (en) 2015-02-09
WO2003103662A2 (en) 2003-12-18
AU2003250825A8 (en) 2003-12-22
CA2488630A1 (en) 2003-12-18
EP1511480A2 (en) 2005-03-09
WO2003103662A3 (en) 2004-11-04
ATE346095T1 (de) 2006-12-15
EP1860118B1 (en) 2014-12-31
EP1511770A2 (en) 2005-03-09
US20050079541A1 (en) 2005-04-14
ZA200409776B (en) 2007-02-28
EP1860118A2 (en) 2007-11-28
EP1511770B1 (en) 2006-11-22
DE60309865D1 (de) 2007-01-04
EP1369128A1 (en) 2003-12-10
JP4722480B2 (ja) 2011-07-13
WO2003104282A2 (en) 2003-12-18
AU2003236704B2 (en) 2010-07-08
WO2003104282A3 (en) 2004-10-14
EP1860118A3 (en) 2008-07-30
SI1511770T1 (sl) 2007-04-30
AU2003236704A1 (en) 2003-12-22
US7514543B2 (en) 2009-04-07
ES2527717T3 (es) 2015-01-28
WO2003104282A8 (en) 2004-04-29
DE60309865T2 (de) 2007-10-18
CN1668721A (zh) 2005-09-14
CN1668721B (zh) 2012-11-14
AU2003250825A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
ES2276078T3 (es) Proteina de fusion glicoproteina vi-fc para el tratamiento de enfermedades vasculares.
US8119135B2 (en) Antibodies which bind to epitopes of glycoprotein VI
US20240181050A1 (en) Agonist antibodies that bind human cd137 and uses thereof
Massberg et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo
US20240002525A1 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
EP1538165A1 (en) Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4
ES2343681T3 (es) Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad.
US12091455B2 (en) Compositions for modulation of a TREM or TREML protein and methods of use
EP3833443A1 (en) Antigen binding agents that bind cd277 and uses thereof
US7531178B2 (en) Immunoadhesin comprising a glycoprotein VI domain